Harnessing the microbiome for the development of diagnosis and therapeutic tools in cancer ! EverImmune is a biotechnology company specialized in the development of live biotherapeutic products in the field of microbiota oncology. It harnesses the gut microbiota for the development of a unique approach aiming to restore the response of Immune Checkpoint Inhibitors (ICIs) in cancer patients. The company is developing Oncobax AK, a Live Biotherapeutic Product (LBP) used as an oral adjuvant to anticancer immunotherapies, designed to safely boost the immune system and restore sensitivity to immunotherapies in primary resistance settings. The company also develops other bacteria in …

123 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Developing mRNA vaccines and therapeutics In September 2021, Sanofi acquired Translate Bio, a clinical-stage mRNA therapeutics company. This acquisition further accelerates Sanofi’s efforts to develop transformative vaccines and therapies using mRNA technology. It adds a critical pillar to the company’s mRNA Center of Excellence, which aims to unlock the potential of next-generation mRNA vaccines and other strategic areas such as immunology, oncology, and rare diseases. Sanofi is dedicated to supporting people through their health challenges. We are a global biopharmaceutical company focused on human health. We prevent illness with vaccines, provide innovative treatments to fight pain and ease suffering. We …

144 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Clinical stage biotechnology company whose vision is to be a trusted and acknowledged leader in the microbiome field. Da Volterra is a clinical stage biotechnology company whose vision is to be a trusted and acknowledged leader in the microbiota field. Our mission is to discover, develop and bring to market safe and novel therapeutic options, preserving patients’ microbiota to prevent and cure life-threatening diseases. We strive to serve patients by transforming the promise of science into innovative treatments which have the power to improve health and save lives.​ Committed to innovation, Da Volterra develops products intended to protect the intestinal …

89 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Kane Biotech has a portfolio of proprietary commercialized products that prevent and remove microbial biofilms. Kane Biotech is developing novel wound care treatments that disrupt biofilms and transform healing outcomes. Biofilms are one of the main contributors to antibiotic resistance in wounds which results in serious clinical outcomes and significant cost. revyve® addresses both biofilms and wound bacteria. revyve® Antimicrobial Wound Gel and revyve® Antimicrobial Wound Gel Spray are US FDA 510(k) cleared. revyve® Antimicrobial Wound Gel is Health Canada approved. revyveTM, revyve®, DispersinB®, coactiv+TM, coactiv+®, DermaKBTM and DermaKB BiofilmTM are trademarks of Kane Biotech. The company is listed on …

61 similar entities Type: SMB Activities: biotech deeptech healthtech Technologies: IoT

Diotheris develops anti-infective microbes to prevent bacterial infections and act against antibiotic resistance We create bacterial therapies of the human skin and mucosal microbiome against pathogenic bacteria. Our first suite of products (NASOFLORE line) targets Staphyloccocus aureus / MRSA (Methicillin resistant S aureus). The products based on live bacteria identified in our clinical and in vitro studies do not generate emergence of antibiotic resistance. antimicrobial, nose microbiome, therapeutics, LBP, Staphylococcus Aureus, and MRSA

71 similar entities Type: Startup Activities: healthtech deeptech biotech Technologies: Synthetic Biology

Developing a maternal vaccine for Group B Streptococcus MinervaX is pursuing the development of a maternal vaccine for the prevention of adverse pregnancy outcomes and life-threating infections caused by Group B streptococcus (GBS). The vaccine is based on adjuvanted proteins antigens covering close to 100% of clinical GBS isolates. Group B Streptococcal (GBS) is the leading cause of life-threatening infections in newborns. Colonization of pregnant women with GBS may lead to adverse pregnancy outcomes such as late abortions, stillbirths, and preterm delivery. Colonization may also lead to life-threatening infections in newborns for the first 3 months of life, causing pneumonia, …

59 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Leading the Microbiome revolution Seres Therapeutics is a commercial-stage company developing novel microbiome therapeutics for serious diseases. Our lead program, VOWSTTM, obtained U.S. FDA approval in April 2023 as the first orally administered microbiota-based therapeutic to prevent recurrence of C. difficile infection (CDI) in adults following antibacterial treatment for recurrent CDI and is being commercialized in collaboration with Nestlé Health Science. We are evaluating SER-155 in a Phase 1b study in patients receiving allogeneic hematopoietic stem cell transplantation to reduce incidences of gastrointestinal infections, bloodstream infections, and graft-versus-host disease as well as additional preclinical stage programs targeting Infection Protection in …

137 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Science to Transform Lives Immunocore is a leading T cell receptor (TCR) biotechnology company working to create first-in-class biological therapies to address unmet patient needs in oncology as well as infectious and autoimmune diseases. See our community guidelines: http://bit.ly/2kFA8hr Biotechnology, Cancer, Oncology, Infectious Diseases, Autoimmune Diseases, T Cell Receptor, Immunotherapy, ImmTAX, ImmTAC, ImmTAV, and ImmTAAI

267 similar entities Type: Startup Activities: deeptech hrtech biotech Technologies: Synthetic Biology

Superior and effective microbiome therapeutics CHAIN Biotechnology was founded in 2014, by serial entrepreneur Dr Edward Green, to exploit the therapeutic potential of Clostridia bacteria found in the human gut microbiome. CHAIN has built an impressive technical team of molecular biology, microbiology, microbiome and fermentation specialists focused on the biotechnology development of Clostridia. In addition, CHAIN leverages synthetic biology expertise from the Synthetic Biology Research Centre at the University of Nottingham. CHAIN has developed a proprietary microbial platform for drug delivery. The platform builds on core engineering skills and involves the development and use of engineered Clostridia to deliver specific …

61 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Redefining microbiome-based therapeutics MRM Health NV is a biopharmaceutical company focused on the discovery and development of innovative therapeutics based on the human microbiome.The company is based in a Center of Expertise for microbiome research and development in the biotech cluster in Ghent, Belgium, and has a strategic partnership with the VIB, with top research groups in both microbiome analysis and ecology and in host biology and disease research. The Company is strategically supported by strong local and international investors, including Ackermans & van Haaren, DuPont, MRM Technologies, Qbic II and VIB and has a corporate collaboration with DuPont Nutrition …

129 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Laigo's SureTAC platform enables rapid therapy development for removal of disease-driving membrane proteins #laigobio Laigo's proprietary SureTAC platform empowers us to rapidly develop first-in-class dual targeted therapies that eliminate disease-driving membrane targets using straightforward bispecific antibody technology. We are committed to exploring an ever-evolving universe of new targets, including those currently considered undruggable, and we are open to strategic partnerships to make meaningful advancements in treating diseases that lack effective treatment options today. Laigo Bio is where innovation meets life-changing solutions, forging a path toward a healthier tomorrow. #TPD #Protac #membraneprotein #bispecificantibody #antibody #proteindegradation #roteindegrader #LaigoBio #oncology #neurobiology #immunology #SureTACs

146 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Vital new drugs for pandemic infections We acquire, develop and license innovative drugs to treat pandemic infections. We have expanded to develop a broader portfolio of new therapies to meet the rising burden of critical priority infectious disease. Based at Alderley Park in the North West of England, our work addresses unmet patient needs and will bring new portfolio of drugs into clinical trials to treat patients suffering from life-threatening infections. Pharmaceuticals, R&D, Antimicrobial Resistance, and Development

147 similar entities Type: Startup Activities: biotech deeptech healthtech Technologies: Synthetic Biology

Mark Smith and Stephen Cork were appointed Administrators on 21 August 2024, and act without personal liability. Destiny Pharma is a clinical stage, innovative biotechnology company focused on the development of novel medicines that can prevent life-threatening infections. Its pipeline has novel microbiome-based biotherapeutics and XF drug clinical assets including NTCD-M3, a Phase 3 ready treatment for the prevention of C. difficile infection (CDI) recurrence which is the leading cause of hospital acquired infection in the US and also XF-73 nasal gel, which has recently completed a positive Phase 2b clinical trial targeting the prevention of post-surgical staphylococcal hospital infections …

236 similar entities Type: SMB Activities: deeptech biotech Technologies: Synthetic Biology

The world's go-to partners for infectious disease biomaterials and testing services. We are the world’s leading experts and go-to collaborators in biological products and services, focused on protecting the health and safety of people around the world. For over 50 years, we have been partnering with healthcare and life science laboratories, manufacturers and suppliers across the globe to co-create and provide biological control materials, assay services and consulting for microbiology, molecular diagnostics and virology. Headquartered in Saint Cloud, Minnesota, we have additional facilities in California, Kentucky and Michigan. Microbiology, Biotechnology, Quality Control, Molecular Microbiology, Contract Research Organization, Virology, Anti-Infective Drug …

207 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Targeted treatment of serious infections mycoBiologics is a University of Aberdeen biotech spinout company which is dedicated to developing new antibody therapies to improve the survival of patients suffering from life-threatening, drug-resistant infections. Antibody therapy, Anti-infectives, Antifungal, Antibacterial, and Drug discovery

298 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Leadership in overcoming the antibiotic resistance crisis. BioVersys AG is a SIX listed (BIOV) clinical stage Swiss pharmaceutical company focusing on research and development of small molecules acting on novel bacterial targets with applications in antimicrobial resistance (AMR) and targeted microbiome modulation. With the company’s two in house technology platforms: i) TRIC and ii)Ansamycin chemistry, BioVersys develops novel, innovative antibacterial drugs, overcoming resistance and modulating the microbiome. By this means, BioVersys addresses the high unmet medical need for new treatments against life-threatening resistant bacterial infections and bacteria-exacerbated chronic inflammatory microbiome disorders. Our most advanced research and development programmes address nosocomial …

63 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

PBD Biotech develops Actiphage, a blood test for human tuberculosis, bovine tuberculosis and Johne’s Disease. PBD Biotech develops Actiphage, a blood test that detects live Mycobacteria, the cause of tuberculosis (TB) in humans and bovine TB and Johne's Disease in animals. One quarter of the world’s population is infected with latent tuberculosis (LTBI), and for one in ten of these people it will progress to active TB disease. As Actiphage detects the presence of active infection, it has potential for a screening test for the disease and to improve drug management. Mycobacteria also cause the diseases bovine TB and Johne's …

57 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Developing Tomorrow's Antibacterials Antabio is a privately held, clinical-stage biopharmaceutical company dedicated to developing novel and highly differentiated antibacterial treatments targeting drug-resistant infections caused by WHO and CDC critical priority pathogens. Guided by scientific excellence and a clear mission, Antabio’s mission is to deliver life-saving therapies that combat antimicrobial resistance (AMR) and help preserve the effectiveness of antibiotics for future generations. Antabio’s lead program, MEM-ANT3310, is a next-generation β-lactam/β-lactamase inhibitor (BL/BLI) combination currently in Phase 1 clinical development. Designed to treat severe hospital infections caused by multidrug-resistant Gram-negative bacteria, MEM-ANT3310 represents a major step forward in addressing one of the …

61 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Leading biotech in the development of innovative microbiome-based biotherapies YSOPIA Bioscience is a clinical-stage biotech company developing cutting-edge biotherapies based on the gut microbiome. Our goal is to bring safe & efficient solutions to patients with high unmet medical needs. Microbiome, Obesity, Gut modulator, Cardiometabolism, Cardiometabolic diseases, Microbiota, and Gut microbiota

298 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

AI-Native Phage Therapy We are facing a global crisis where bacterial infections are becoming increasingly deadly due to antibiotic resistance. The health and economic consequences are staggering, with bacterial disease predicted to be the #1 cause of death by 2050. Alternatives are urgently needed, but nature already has its solution: phages, the natural predators of bacteria. At Phagos, we are bringing back phage technology by combining advances in microbiology with cutting-edge artificial intelligence. Our patented technology makes large-scale, customized phage-based veterinary medicines possible for the first time. And soon we'll universalize the technology for human health too. Our mission is …

65 similar entities Type: Startup Activities: biotech healthtech Technologies: Decarbonization

Bringing People & Ressources Together The creation of Genbiotech, a spinoff of the Laboratoires Genévrier results of 15 years of strategic involvement in biotechnological research with one goal: to improve the quality of life of patients in the field of rheumatology, dermatology and aesthetic. We believe that tomorrow medicine needs to be dedicated and targeted to patients. We aim to improve existing treatments by using non invasive processes allowing local and sustained administration of biological and active molécules. The company, incepted in 1998, has currently a staff of 11 people and is located in Sophia Antipolis (South of France). For …

633 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Targeting protein interactions for health Founded in 2023, TheraPPI Bioscience is a biotechnology company whose science originates from the CRCL (Centre de Recherche de Cancérologie de Lyon, France). We modify protein interactions to offer treatments where current therapies fail. Our approach represents a paradigm shift in tackling cancer resistance and non-curable rare diseases protein-protein interaction, PPI, small molecule, therapeutics, oncology, and rare disease

216 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

goes FAR BEYOND (Fighting Antimicrobial Resistance to the Biological EmergencY to Opportunistic and Neglected Diseases) Dimicare Biotech is a project from Université Côte d'Azur, INSERM and CNRS focused on the development of novel "precision" antimicrobial drugs to fight multidrug-resistant infections. Our main project focuses on the development of a new treatment against multidrug-resistant S. aureus strains (including the WHO priority MRSA; methicillin-resistance S. aureus strains). Currently, this treatment is in the early-preclinical phase where its efficacity against several clinical strains and its innocuity in Human cells has been confirmed. Dimicare Biotech is building a great team involving Microbiology Medical doctors, …

171 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

The KELTICPharma team combine academic innovation, deep target knowledge and corporate drug discovery expertise. In 2019 Prof Andrew Tobin published validation of PfCLK3 as a target with breakthrough potential in the treatment of malaria. Successful drug development would provide a single medicine that is curative, transmission blocking and prophylactic.

202 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Subsidiary of BioNTech SE, now trading as BioNTech R&D (Austria). Developing novel anti-bacterials. BioNTech R&D Austria GmbH (formerly: PhagoMed Biopharma GmbH) is a fully owned subsidiary of BioNTech. The team in Vienna focuses on developing novel anti-bacterial drugs for persistent bacterial infections. Biotech

61 similar entities Type: Startup Activities: biotech deeptech healthtech Technologies: Synthetic Biology

A Joint Venture with Unilever PLC, creating a world free of harmful Biofilms though novel technology inspired by Nature. Were are a Joint Venture initiative with Unilever PLC formed in late 2019 with exclusive rights to the commercialise a new and novel technology based on furanone chemistry that inhibits Biofilms. Inspired by the biology of red seaweed, this single molecule platform offers a sustainable low-toxicity alternative to existing biocides. It has activity against bacteria by blocking quorum sensing and communication through multiple identified molecular targets in the bacteria, but is also effective against moulds and algae making this a unique …

63 similar entities Type: Startup Activities: deeptech biotech Technologies: Bio sourced materials

Microbial solutions and microbiome skincare with live bacteria In Lactobio we focus on the creation of new microbiome and microbial solutions to target and fight the problem of increasing infections caused by microorganisms being resistant to antibiotics. We work with the skin, vaginal, and gut microbiota to treat a variety of diseases – with projects spanning various pathogens. Lactobio has obtained very promising clinical results, with isolated lactic acid bacteria having a significant antibacterial activity against Staphylococcus aureus, Methicillin Resistant Staphylococcus aureus (MRSA) and other pathogens.

55 similar entities Type: Startup Activities: deeptech biotech

Focusing on Resistance in Antibiotic Development Qpex Biopharma, Inc. a Shionogi Group Company, is a resistance-focused infectious disease company on a mission to make both a dramatic and sustainable improvement in patient care. Leveraging a multi-faceted approach and a deep understanding of drug resistance mechanisms, we are creating novel products and development. strategies that overcome multi-drug resistance. We are advancing a robust portfolio of treatments that will bring innovation to antibiotic development and deliver the right treatments to the right patients in the right settings. During the previous decade, our team brought 4 antibiotic products to regulatory approvals, with an …

79 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Radically accelerating human healthcare By combining machine learning with advanced chemistry, inBiome enables microbiology labs around the world to rapidly and easily identify bacteria in a wide range of clinical sample types, including complex microbiota. Even uncultivable and antibiotic-treated species are detected. Current applications include replacing traditional culture in ICUs for more accurate, same-day results, infection control, gut flora analysis, and various r&d applications for healthcare, pharmacy, and food industries. Promising new applications currently undergoing clinical trials include IBD and Sepsis diagnostics and preventive screening. Molecular Diagnostics and Bacterial infections

80 similar entities Type: Startup Activities: deeptech biotech Technologies: A.I.

Iterum Therapeutics plc is an Ireland-based clinical-stage pharmaceutical company dedicated to developing differentiated anti-infectives. These products are aimed at combatting the global crisis of multi-drug resistant (MDR) pathogens to significantly improve the lives of people affected by serious and life-threatening diseases around the world. Iterum’s first product is a novel anti-infective compound that has demonstrated potent in-vitro activity vs. a wide variety of gram-negative, gram-positive and anaerobic bacteria resistant to other antibiotics. For more information on Iterum Therapeutics please visit www.iterumtx.com.

64 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Evolution. Adaptation. Future. Phage-based solutions to combat bacteria. - Prevention - Diagnosis - Treatment "One Health" personalized treatments. biotecnología, microbiología, investigación, biomedicina, bacteria, phage, and phage therapy

185 similar entities Type: Startup Activities: biotech deeptech healthtech Technologies: Synthetic Biology

Developing first-in-class therapies designed to defeat chronic inflammation and fibrosis at the source. Our innovative therapeutic approach targets upstream amplifiers of disease offering potential treatments across a diverse array of therapeutic indications. Calluna Pharma is a clinical stage biotech company driven by a commitment to improve patient outcomes in diseases where existing treatments are sub-optimal. We believe in the power of immunology to push boundaries, challenge the status quo, and develop therapies that will make a real difference for people living with serious diseases.

202 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Glox Therapeutics Ltd. is developing novel precision antibiotics based on protein bacteriocins, which have potent narrow-spectrum activity to target Gram-negative Antimicrobial Resistant (AMR) pathogens.

160 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

We Empower Cells In Vivo to Fight Diseases. EsoBiotec is a biotechnology company developing innovative therapeutics to fight cancer. Our mission is to empower the human body to tackle cancer by bringing in vivo engineering of cells to patients. We aim to develop cost-effective and off-the-shelf therapeutics and providing state-of-the-art cell therapies to maximise accessibility. Our disruptive approach holds the potential to transform the current standard of cell and gene therapies for cancer treatment. Gene therapy, Biotechnology, Oncology, Cell therapy, Cancer, in vivo engineering, virology, and Immunology

216 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Developing a novel antibiotic regimen with ability to act on a wide range of multi-drug resistant bacteria. Thioredoxin Systems AB is a biotechnology company developing a novel antibiotic regimen against pathogenic bacteria. EbsArgent is a patented combination of ebselen and silver, capable of functioning as an antiseptic, antibacterial in food production, and as a medicinal product. With its versatility and ability to act on a wide range of multi-drug resistant bacteria, it is among the most promising antibiotic regimen under development today.

68 similar entities Type: SMB Activities: biotech healthtech deeptech Technologies: Synthetic Biology

Vaccines against antibiotic-resistant infections Headquartered in Seville, Spain, Vaxdyn works with an international network of collaborators in the development of multi-pathogen vaccines for preventing antibiotics-resistant infections in all regions of the world. Our vaccines target high-risk populations, population affected by chronic diseases of the lungs, liver, kidney, immunocompromised by co-morbidities like diabetes or cancer, populations associated with nursing homes and hospital settings, women affected by recurrent urinary-tract infections, or neonates. We are strongly committed to contribute to reducing antibiotic use in the world by following a One-Health approach. Vaxdyn is the first Spanish biotech funded by CARB-X. CARB-X awarded Vaxdyn …

76 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Founded in 1951 by pharmacists and microbiologists, biose® has 60-year experience in drug based on live bacteria, giving us a deep understanding of the entire process from discovery to commercialization. Focused on Health through microbiota and microbiome science, we use our skills for the discovery, product development, clinical studies and manufacturing of Live Biotherapeutic Products (LBPs). Our company is drug-GMP certified for the manufacturing of bacteria-based APIs, clinical and commercial products. Microbiome Therapeutics, live biotherapeutics, LBPs, and CDMO

127 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

From Microbes to One Health. Taylor made R&D to tackle infectious diseases. Vibiosphen is a SME healthcare biotechnology in infectious diseases founded in 2014. Given the important and interdependent human, animal, and environmental dimensions of antimicrobial resistance, the One Health concept promotes a global effort to achieve the best health for people, animals, and the environment. In this context, Vibiosphen takes part of the efforts that are underway to develop new anti-infective therapies, to rejuvenate the antibiotic pipeline, develop novel antibiotics, and discover innovative therapeutic strategies for priority pathogens. Based on its pluridisciplinary and integrated approaches, Vibiosphen, with more than …

63 similar entities Type: Startup Activities: biotech deeptech manufacturing Technologies: Synthetic Biology

Sinnotest® supports rheumatologists in optimizing the prescription of biotherapies in rheumatology SINNOVIAL is a biotechnology company that develops personalized medicine devices to improve the management of Chronic Inflammatory Rheumatism (RIC) in Rheumatology (rheumatoid arthritis, ankylosing spondylitis, in particular). Our mission: to improve the quality of life of patients by maximizing the chances of success of their treatment with biotherapy. Our objective: to provide the doctor with a device to assist in therapeutic orientation which allows him, in real time, to optimize the selection of biotherapy. “The right treatment, to the right patient, at the right time!” » Biotechnology, Rheumatology, Medtech, …

103 similar entities Type: Startup Activities: biotech deeptech healthtech Technologies: Synthetic Biology

RELIEF THERAPEUTICS Holding SA (SIX: RLF; OTCQB: RLFTF, RLFTY) We are a biopharmaceutical company committed to providing therapeutic relief to patients living with rare diseases. Our goal is to advance treatment paradigms and deliver improvements in efficacy, safety and convenience to benefit the lives of patients and their families. Our therapeutic focus is on rare indications for metabolic disorders, pulmonary diseases, and dermatology/connective tissue disorders. Acute Lung Injury, Pulmonary Sarcoidosis, Lung Fibrosis, Acute Respiratory Distress Syndrome, Urea Cycle Disorders, Maple Syrup Urine Disease, Rare Diseases, Epidermolysis Bullosa, Phenylketonuria, PKU, EB, MSUD, UCD, ARDS, Rare Disease, Metabolic Disorders, Acute Lung Disease, …

260 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Tackling bacterial infections, antimicrobial resistance, and their consequences in acute care settings. AUROBAC THERAPEUTICS is a biopharmaceutical company founded in 2022 by three highly renowned life sciences innovation companies, Boehringer Ingelheim, Evotec and bioMérieux, to become a global leader in the fight against bacterial infections, Antimicrobial Resistance (AMR) and their consequences in acute hospital settings. AUROBAC’s R&D strategy addresses these unmet medical needs with patient- and pathogen-targeted programs designed to tackle both the causes and consequences of potentially life-threatening bacterial infections and AMR, including hospital-acquired and ventilator-associated bacterial pneumonia (HABP and VABP) and sepsis.

60 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Fabentech is a privately owned biopharmaceutical SME based in Lyon (France) and created in 2009, which develops immunotherapies to address situations of emergency. In an environment where the globalization of trade accelerates the spread of epidemics and where the geopolitical context increases the risk of bioterrorist attacks, nations should be prepared to address various situations of public health & medical emergency. However, there is generally no real therapeutic option to fight acute symptoms arising from these neglected indications. Based on its horse F(ab’)2 platform, a fully-derisked technology in-licensed from Sanofi Pasteur, Fab’entech aims to provide therapeutic solutions in the fields …

106 similar entities Type: Startup Activities: biotech deeptech healthtech manufacturing Technologies: Synthetic Biology

Aseptix Health Sciences is a global leader in next generation antimicrobials, specializing in novel and patented infection prevention products and technologies for medical, professional and consumer use. Aseptix’ sustainable antimicrobial technologies enable products to safely, effectively and quickly kill contagious pathogens and are used in a wide range of applications, industries and therapeutic areas. The Company markets its products and technologies through a combination of Aseptix branded and third party branded products, and licenses on its portfolio of patented technologies to global industry leaders in their markets. The corporate mission is to become the global alternative for user unsafe and …

75 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Creating a global leader in extended phage therapies PHAXIAM is a biopharmaceutical company developing innovative treatments for resistant bacterial infections, which are responsible for many serious infections. The company is building on an innovative approach based on the use of phages, natural bacterial-killing viruses. PHAXIAM is developing a portfolio of phages targeting 3 of the most resistant and dangerous bacteria, which together account for more than two-thirds of resistant hospital-acquired infections: Staphylococcus aureus, Escherichia coli and Pseudomonas aeruginosa. PHAXIAM is listed on the Nasdaq Capital Market in the United States (ticker: PHXM) and on the Euronext regulated market in Paris …

61 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

LinKinVax aims at creating a universal, safe, enduring, vaccines platform against multiple pathogens. We are a clinical stage Biotech Spin-off of the Vaccine Research Institute in France with a unique "DC targeting" platform covering infectious desaeses and oncology.

133 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

A nature-inspired solution to trap pathogens @AIS Biotech (with AIS for Anti Infective Sugar) is a French Biotech company based in the @Région Auvergne-Rhône-Alpes, France, incorporated in March 2023 with the objective of developing a new class of sugar-based anti-infective biotherapeutics to fight (re)emerging infectious diseases. Thanks to a Bioengineering plateform based on the expertise of the leading edge academic laboratory @CERMAV (@CNRS, @UGA, Grenoble, France), AIS Biotech aims to develop a pipeline of innovative sugar-based biopharmaceuticals which can prevent or treat infections by mimicking the natural host surface oligosaccharide binding-sites of pathogens. GlycoFlu, our first drug-candidate validated at the …

80 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

At the forefront of the fight against antibioresistant bacteria Pherecydes Pharma develops antibacterial treatments based on the use of bacteriophage viruses, or phages, to fight bacterial infections in humans, particularly those resistant to antibiotics. Phages are natural predators of bacteria and have no demonstrated effect on eukaryotic cells, including human cells. Antimicrobial resistant bacteria or AMR are responsible for over 700,000 death a year in 2014 according to the WHO. This number might reach over 10,000,000 by 2050 if nothing is done, and no new class of antibiotics has been discovered in the last 30 years. Phages represent one of …

60 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Transforming lives with personalised, accessible, adaptive phage therapy to help clinicians cure complex infections Our mission is to transform lives with personalised, accessible, adaptive phage therapy that cures difficult bacterial infections and restores hope for patients. To ensure every bacterial infection can be effectively treated and to restore hope for patients with no remaining options.

61 similar entities Type: Startup Activities: healthtech deeptech

Captor Therapeutics is a publicly-listed (WSE:CTX) innovative drug discovery and development company focused on targeting the undruggable proteome using targeted protein degradation. Our mission is to transform lives of patients suffering from cancer, autoimmunity and neurodegenerative diseases. Our groundbreaking technology is perfectly suited to create new drug candidates with the potential to ease patients' burden and cure conditions that so far have only been poorly treatable. Captor Therapeutics S.A. implements projects co-financed by the European Union. All information about the projects is available at: https://captortherapeutics.com/grant-projects. drug development, biotechnology, and protein degradation

734 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Amicus Therapeutics is now part of BioMarin Pharmaceutical Inc., a leading, global rare disease biotechnology company focused on delivering medicines for people living with genetically defined conditions. For more information on BioMarin, please visit https://www.biomarin.com/ and follow @BioMarin Pharmaceutical Inc. on LinkedIn for updates.

109 similar entities Type: SMB Activities: deeptech biotech Technologies: Synthetic Biology

Nosopharm is an innovative biotechnology company headquartered in Lyon (France) and specialized in the research and development of new molecules to combat antimicrobial resistance (AMR). The mission of Nosopharm is to discover and develop novel first-in-class anti-infectives addressing unmet medical needs. The innovative anti-infective drug discovery platform developed by Nosopharm is based on the therapeutic exploitation of a very original bioresource: the bacterial genera Xenorhabdus and Photorhabdus. Anti-Infectives, Drug Discovery, Antibiotics, and Microbiology

Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

A new way to tackle chronic refractory infections ! Santero Therapeutics is a Belgian biotechnology company developing first-in-class medicines for chronic treatment-refractory infections. Founded in 2021 as a spin-off from the Université Libre de Bruxelles (ULB), the company builds on nearly 20 years of foundational research into the mechanisms governing bacterial survival and persistence. Based in Mont-Saint-Guibert, Belgium, Santero's team of scientists and professionals is advancing a platform of RSH enzyme inhibitors with the potential to transform outcomes for patients living with chronic infections that current treatments cannot resolve. biotechnology , pharma, refractory infection, chronic treatment, and bacteria

74 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Developing technologies for the biopharma industry to allow them to treat the root causes of diseases and disorders. Based in Lausanne, Switzerland, NewBiologix SA is a technology innovation company developing a proprietary and breakthrough DNA integration platform for the advanced engineering of human and mammalian cell lines for the improved production of viral vectors used in gene therapies. gene therapy, cell therapy, next-generation sequencing, NGS, rAAV, viral vectors, biologics, stable cell lines, Genomic Integration, stem cell, bioinformatics, capsid optimization, HEK293, gene expression, ATMPs, genomic, epigenetic, transcriptomic, mammalian cell lines, and human cell lines

206 similar entities Type: SMB Activities: deeptech biotech Technologies: Synthetic Biology

Smarter antibiotics for a healthier tomorrow. smartbax is a German biotech startup, founded in Munich in 2021, dedicated to developing innovative antibiotics to combat the rising threat of multidrug-resistant bacteria. Our vision is to create smarter antibiotics for a healthier tomorrow. By combining cutting-edge technology with deep scientific expertise, our team designs drugs to outsmart bacterial resistance – addressing one of the most urgent threats to global health. At smartbax, we believe preventing a crisis tomorrow means taking action today. antibiotics

62 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

To make disease-modifying treatments available to patients with serious or life-threatening conditions Medibiofarma S.L is a clinical-stage biotechnology company founded in 2016 by a group of professionals with extensive experience in Drug Discovery in the pharmaceutical industry. We aim to generate innovative and high quality research programs based on the modulation of clinically validated therapeutic targets for the treatment of cancer and non-cancer diseases. Medicinal Chemistry, in vitro Pharmacology, Drug Discovery and Development, IP generation, IBD (Colitis, Crohn), Oncology, CNS, and Synaptopathies

630 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Multi-target cell and gene therapies for unmet medical needs. Aurealis Therapeutics is a Swiss-Finnish Cell and Gene Therapy Platform Company. Our multi-target cell and gene therapies, based on genetically modified safe lactic acid bacteria, address unmet medical needs: Chronic Wounds - Diabetic Foot Ulcers, Venous Ulcers, Pressure Ulcers - deadly Cancers - Ovarian Cancer, Peritoneal Carcinomatosis - Inflammatory diseases. After successfully completing Phase 1 and Phase 2 clinical studies in Diabetic Foot Ulcer (DFU) with our lead asset AUP-16, we're actively preparing a global DFU Phase 3 study. Other indications will follow In Oncology, we are building on impressive pre-clinical …

193 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

rethinking microbiome Mikrobiomik is a biopharmaceutical company created for the research and development of therapies based on the human microbiome. Our Mission At Mikrobiomik we develop innovative therapies based on intestinal microbiota to offer new therapeutic options in serious diseases with unmet medical needs. Through our FSPIM® technology, we work to restore the balance of the microbiome and provide healthcare professionals and patients with safe, standardized and accessible therapeutic solutions in clinical practice. Fecal microbiota transplant (FMT)

63 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Phico Therapeutics is a biotechnology company advancing the war on antibiotic resistance with engineered phage therapy. At Phico, we are developing a unique antibiotic technology to address one the most urgent challenges facing medicine today – how to destroy multi-drug resistant bacteria, the so-called “superbugs”. Our patented platform utilises an antibacterial protein, SASP to inactivate bacterial DNA and cause rapid destruction of target bacteria. With a number of advantages over conventional antibiotic classes, SASPjectTM could form the basis for a new generation of antibiotics to overcome antimicrobial resistance. Watch our animation to discover how our technology works: https://www.youtube.com/channel/UCjPndK0F9ufmEy9fBQFTsUg Twitter: @Phicotx …

65 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

End-to-end phage company safeguarding human and animal health by harnessing sustainable, antibacterial technology. NexaBiome's patented technology enables bacteriophages to be covalently attached to a wide variety of substrates. This gives them enhanced stability for use in a variety of applications which address two of the world's major challenges: antibiotic resistance and diabetic foot infections. By attaching specific bacteriophages to wound dressings and other substrates, we can reduce, augment or even substitute for antibiotics in human health. This lets us target disease-causing bacteria such as S. aureus, E. coli, Listeria, Campylobacter, Salmonella, Streptococcus, Pseudomonas and others. As our bonded phage products …

56 similar entities Type: Startup Activities: biotech deeptech Technologies: Decarbonization

Transforming lives with groundbreaking treatments Coultreon Biopharma's mission (formerly Onco3R Therapeutics) is to develop life-changing medicines for patients affected by chronic inflammatory diseases of high unmet medical needs. The team is leveraging their knowledge and expertise to bring transformative innovations to patients suffering from auto-immune diseases. In this field, there is an urgent need for more convenient oral drugs that can offer greater efficacy with a better safety profile. Drug Discovery, Drug Development, Immunology, Biotech, and R&D

826 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Orchestrating gut health® EnteroBiotix is a leading microbiome therapeutics platform company that is focussed on transforming the standard of care for patients battling debilitating diseases and infections linked to disruptions to structure and function of the gut microbiome.

143 similar entities Type: Startup Activities: deeptech biotech healthtech Technologies: Synthetic Biology

Better Technology. Better Delivery. Developing a new generation of disease-modifying therapies. Driven by our proprietary Enhanced Delivery Oligonucleotide (EDO) platform, we are creating a pipeline of disease-modifying therapeutics with the potential to safely and effectively target the root cause of serious genetic neuromuscular and neurological disorders. Biotechnology, Chemistry, Biology, Bioscience, Life sciences, and Therapeutics

296 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

a wholly owned subsidiary of Eli Lilly and Company LimmaTech Biologics AG, a wholly owned subsidiary of Eli Lilly and Company, is a Swiss-based clinical stage biopharmaceutical company. We are advancing our proprietary vaccine pipeline to halt the increasing threat of global infections due to emerging antibiotic resistance (AMR) and sexually transmitted diseases. vaccines, research & development, biotechnology, and antimicrobial resistance

419 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

We’re using ground-breaking cell technologies to revolutionise global food production - starting with pork Uncommon Bio began with cell-based meat and pioneered RNA delivery innovations, which evolved into their most recent spin out which is focusing on changing medicine through multi-targeting. Their polysaccharide-based delivery platform enables multi-pathway cell programming, offering a safe, efficient and scalable alternative to multi-target therapies. The company is initially targeting severe lung diseases like idiopathic pulmonary fibrosis and is backed by industry leaders from BioNTech and top investors, including Sam Altman, Balderton, Lowercarbon, and Redalpine. science+art, biotech, mRNA, IPF, Pulmonary fibrosis, and delivery

561 similar entities Type: Startup Activities: biotech deeptech foodtech Technologies: Synthetic Biology

We provide innovative in-vitro diagnostic platforms for antibiotic susceptibility testing. Redefining Bacterial Infection Management: Setting a New Standard of Care Antimicrobial Resistance, In vitro Diagnostics, Antimicrobial susceptibility testing, and Clinical Microbiology

85 similar entities Type: Startup Activities: healthtech deeptech Technologies: SaaS

Pioneering first-in-class, small-molecule therapies for immune-mediated and oncologic disorders We are a clinical-stage biotechnology company combining courage, conviction and cutting-edge science to develop breakthrough treatments for immune-mediated and oncologic disorders, with the hope of helping patients overcome their disease and live a better life. We are pioneering first-in-class, small-molecule therapies that harness master regulators of cellular function and inhibit multiple drivers of disease via a single target. In modulating the function of profound intracellular regulators, our medicines have the potential for significant clinical impact in the most difficult-to-treat diseases. We believe the wide-ranging impact of our therapeutic platforms can be …

435 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Ilya Pharma 🇸🇪🇺🇸 is bringing local-acting immunotherapies to patients Delivering local-acting immunotherapies to patients ATMP, Gene Therapy, Drug development, Clinical trials, GMP, IBD, Wound treatment, Scar, Topical, Oral, Research, Science, Immunology, Immunophysiology, microbiology, Applied microbiology, Regulatory excellence, Skin, Diabetes, IBD, Cysticfibrosis, SAVI, colitis, Cystic fibrosis, and Inhalation

646 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Pioneering the development of microbiome-based therapies using proprietary tools for their design and production. PharmaBiome is a privately-held spin-off company of ETH Zurich and a pioneer in the production of live biotherapeutic products to address disturbances of the gut microbiome. It has developed the first-in-the-industry, patent-protected technology platform for the production of standardized microbiome-based products. Founded in Zurich in 2015, at the intersection of microbiology, biotechnology, and data science, PharmaBiome believes that the future of microbiome-based therapeutics lies in developing the biotechnology needed to produce a solution compatible with the safety, efficiency, and trial requirements of any human medicine. This …

92 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Developing first-in-class solutions for unmet health and personal care needs Results through innovation. We are an innovative biotechnology group with two divisions. Our consumer health arm has commercial products for the personal care market addressing nail, skin, scalp and hair issues. NovaBiotics pharma division has advanced clinical-stage product candidates for medically unmet, life-limiting inflammatory, infectious and respiratory disease. Our highly disruptive solutions to personal care and health needs address significant global markets. biotechnology, biologics, infectious disease, and drug discovery & development

225 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

First-in-class wound dressings with nanotechnology aiming to prevent infection and promote wound closure. Nanordica Medical is an Estonian MedTech company. We are pioneers in advanced antibacterial nanotechnology preventing and curing topical bacterial infections. The company applied for several international patents and developed its first product, an advanced antibacterial wound dressing. A randomized clinical trial in the largest Estonian hospital showed Nanordica's wound dressing cures wounds that can not be cured with other methods and causes fewer adverse effects compared to the current leading antibacterial dressing. Our long-term goal is to be a world-renowned global deep tech company developing and manufacturing …

64 similar entities Type: SMB Activities: manufacturing healthtech deeptech nanotech Technologies: Synthetic Biology

Leading the creation of transformative, first-in-class anti-infectives for life-threatening respiratory infections Aridis Pharmaceuticals is a late-stage clinical development company leading the creation of transformative, first-in-class anti-infectives for life-threatening respiratory infections. The company’s pipeline of novel mechanism antibacterial and antivirals, sprung from its proprietary technology platforms, are designed to combat the growing public health threat of antimicrobial resistant bacteria (AMR). Monoclonal Antibody , Infectious Disease, Cell line Engineering, Inhalation therapy

147 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Investing dark biodiversity DEINOVE is a French biotechnology company pioneering the exploration of a new domain of life, unexplored at 99.9%: the microbial dark matter. By revealing the metabolic potential of rare bacteria or still classified as uncultivable, it tackles a global health and economic challenge: antimicrobial resistance. The new therapies discovered and developed by DEINOVE (antibiotics, antifungals, antivirals and antiparasitics) target superbugs (microbes that resist to one or several antimicrobials) that cause life-threatening infections which are now spreading at high speed. This breakthrough approach gave birth to one of the World first specialized micro-biotechnology platforms and a unique collection …

72 similar entities Type: SMB Activities: biotech deeptech

Harnessing beneficial bacteria to treat chronic inflammatory skin conditions. MatriSys Bio is a clinical stage Specialty Biopharmaceutical Company focused on the $142 Billion WW dermatology and skin care market. We are developing therapies for the top 5 dermatology & skin care conditions - Atopic Dermatitis, Rosacea, Psoriasis, Acne, and Skin Infections, which have a huge impact on quality of life. More than 230 million patients suffer from these 5 skin diseases, which represent a $12.9 Billion Rx market and a $121 Billion skin care market. MatriSys Bio’s scientific approach is to rebalance the natural skin microbiome by application of microbial …

65 similar entities Type: Startup Activities: deeptech healthtech biotech Technologies: Bio sourced materials

Mission We harness the power of molecular microbiology to develop diagnostic solutions that will optimize the treatment of life-threatening, drug resistant infections. We seek to dramatically transform patient care to guide antibiotic therapy selection and help improve antibiotic stewardship. About Headquartered in Rockville, Maryland, OpGen (NASDAQ:OPGN) is a precision medicine company harnessing the power of molecular diagnostics to help combat infectious disease. Our innovative approaches to infectious disease diagnostics consist of highly multiplexed syndromic molecular panels to address the global threat of antimicrobial resistance (AMR), improve antibiotic stewardship, and decrease the spread of multidrug-resistant microorganisms (MDROs). Together we improve patient …

67 similar entities Type: SMB Activities: biotech deeptech Technologies: A.I. Synthetic Biology

Technology-driven biotech with an AI-powered miniprotein RnD platform VRG Tx is technology-driven biotech with a drug discovery platform that integrates AI with wet lab processes to develop next-generation therapeutics. Our vision is to cure diseases through previously undruggable targets and inaccessible mechanisms of action. medicinal biotechnology, research, immunology autoimmune deases , translational health research, use of genetic engineering in medicine, anti cancer drug discovery, oncological drugs, autoimmune diseases, translational research, peptide, cellandgenetherapy, and genetherapy

589 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

An immunotherapy company focused on infectious diseases Centauri Therapeutics Limited is a UK-based biotechnology company focused on the discovery and development of novel molecules targeting life threatening diseases. The Alphamer technology is based on "programmable immunity"​ in which chemically synthesised molecules redirect naturally occurring antibodies to selected pathogens to fight the infection. The molecules have two distinct parts: one end binds a cell-surface target on the pathogen using an aptamer whereas the other end presents specific epitopes that attach to the circulating antibodies. It has been demonstrated that Alphamers have the potential to redirect pre-existing antibodies to bacteria in a …

78 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Discovering & developing novel anti-infectives to treat multi-drug resistant bacterial & hard-to-treat viral infections. Venatorx Pharmaceuticals is a private pharmaceutical company that is focused on the discovery and development of novel anti-infectives to treat multi-drug-resistant (MDR) bacterial infections and hard-to-treat viral infections. antibiotics, antiinfectives, antivirals, drug development, drug discovery, pharmaceuticals, #battlesuperbugs, #WorkingToFightAMR, clinical, research, #squashsuperbugs, biotech, and antimicrobialresistance

91 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Modulating innate immunity to improve cancer therapy outcomes. . Akthelia Pharma is a late preclinical-stage immunotherapy company, with its HQ in Iceland, targeting a huge unmet opportunity to improve cancer and cell/organ transplant outcomes through reducing the risk of neutropenic sepsis. This potentially fatal complication of systemic anticancer treatment, where a combination of reduced neutrophil count and loss of GI integrity results in bacteremia from the patient's own microbiome, is the leading cause of death associated with chemotherapy (up to 20% mortality) -- other than disease progression. Our breakthrough patented strategy, which is supported by world-leading KOLs, is to specifically …

84 similar entities Type: Startup Activities: deeptech Technologies: Synthetic Biology

Formulating the Future of BiologicsTM Elektrofi is a biopharmaceutical formulation technology company that is revolutionizing the delivery of biologic therapies by giving patients the ability to control how they want to receive and benefit from life-changing medicines. Our breakthrough hyper concentration microparticle technology platform, HyperconTM, resolves the limitations associated with intravenously delivered biologic therapies by enabling convenient at-home subcutaneous self-administration. With a focus on monoclonal antibodies, therapeutic proteins, and other large molecule drugs, we create, develop, and commercialize subcutaneous biologic therapies in collaboration with strategic partners. We believe a patient-centered healthcare approach can lead to a healthier world. We are …

276 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

A global MedTech company developing safe and biocompatible technology to prevent medical device related infections Bactiguard is a global MedTech company developing safe and biocompatible technology to prevent medical device related infections. The unique technology is based on an ultra-thin noble metal coating that prevents bacterial adhesion and biofilm formation on medical devices. The company focuses on five strategic therapeutic areas where infection rates create high medical needs for infection prevention. These areas include Orthopedics, Cardiology, Neurology, Urology, and Vascular Access. Bactiguard operates through license partnerships with leading global MedTech companies that apply the technology to their medical devices. The …

87 similar entities Type: SMB Activities: healthtech deeptech Technologies: Synthetic Biology